Pharmaceutical Intermediates Hair Growth Powder Finasteride Proscar
1, Product Name: Finasteride
2, CAS : 98319-26-7
3, MF: C23H36N2O2
4, MW: 372.55
5, Finasteride content: 99%
6, Quality standard: USP/EP
7, Packing: as your reuire
8, Appearance: off-white crystalline powder
9, Storage: Stored and protected from light.
10, Other Hair Loss Treatment Powder: Finasteride, Minoxidil, Minoxidil Sulfate
Usage of Finasteride:
►►►Benign prostatic hyperplasia:
Physicians use finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate. The FDA-approved dose is 5 mg once a day. Six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits reverse within about 6–8 months. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.
►►►Male pattern baldness:
Three Phase 3 clinical trials examined the efficacy of finasteride in the treatment of mild to moderate male pattern baldness. The primary endpoints of each trial were hair count and user self-assessment. Secondary endpoints included investigator assessment and examination of scalp photographs. Each patient also filled out questionairres regarding sexual health and non-scalp body hair growth.
Across all three trials, at one year men taking Propecia had 107 more hairs per 1 inch diameter section of scalp (in the area affected by hair loss) than men treated with placebo. At two years the difference was 138 hairs. Maximum hair gain occurred during the first two years, but because hair loss was more rapid in the placebo treated group, the difference between treated and placebo groups increased to 277 hairs per inch circle at 5 years. Self assessment showed that treated patients perceived an improvement in hair density and overall appearance. These results were supported by investigator ratings and by independent readers examining scalp photographs.
At the end of the first year, the sexual health questionaire revealed differences in sexual interest, erections, and perception of sexual problems that favored the placebo group. However, no significant difference was seen in the question on overall satisfaction with sex life.
White or almost white crystalline powder.
Melts at about 257°C
|Assay (HPLC, based on drying) |
98.5% ~ 101.0% calculated on
Corresponds to spectrum of
USP Finasteride RS
Retention time of major peak
of Assay preparation
corresponds to USP Finasteride
Corresponds to spectrum of USP
Retention time of major
peak of Assay preparation
corresponds to USP
Finasteride RS preparation
|Specific rotation||-56.0°~ -60.0°||-57.5°|
|Melting Point||Melts at about 257°||complies|
Free soluble in Chloroform and
in alcohol,very slightly soluble
|Water (Method I)||≤0.3%||0.16%|
|Residue on ignition||≤0.1%||0.07%|
|Heavy metals (Method II)||≤10 ppm||Complies|
|Chromatographic purity||Single largest impurity: ≤0.5%||0.09%|
| ||Total impurities: ≤1.0%||0.28%|
|Particle size||100% < 30 micron||Complies|
| ||90% < 25 micron||Complies|
The test product complies with the requirements of USP36.